Page last updated: 2024-08-21

pyrazines and Agammaglobulinemia

pyrazines has been researched along with Agammaglobulinemia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clifford, H; Hardy, AT; Hughes, CE; Huissoon, AP; Malcor, JD; Montague, SJ; Nicolson, PLR; Nock, SH; Pollitt, AY; Pratt, G; Thomas, MR; Tomlinson, MG; Watson, CN; Watson, S; Watson, SP	1
Bernlochner, I; Busygina, K; Denzinger, V; Lorenz, R; Siess, W; Weber, C	1
Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C	1

Reviews

2 review(s) available for pyrazines and Agammaglobulinemia

Article	Year
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? Thrombosis and haemostasis, 2019, Volume: 119, Issue:8 Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis	2019
[Multiple myeloma and intravenous immunoglobulins]. La Revue de medecine interne, 2007, Volume: 28 Spec No 2 Topics: Agammaglobulinemia; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins, Intravenous; Infections; Male; Multicenter Studies as Topic; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Time Factors	2007

Article

Year

Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?

Thrombosis and haemostasis, 2019, Volume: 119, Issue:8

Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis

2019

[Multiple myeloma and intravenous immunoglobulins].

La Revue de medecine interne, 2007, Volume: 28 Spec No 2

Topics: Agammaglobulinemia; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins, Intravenous; Infections; Male; Multicenter Studies as Topic; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Time Factors

2007

Other Studies

1 other study(ies) available for pyrazines and Agammaglobulinemia

Article	Year
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. Haematologica, 2018, Volume: 103, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Benzamides; Blood Platelets; Carrier Proteins; Genetic Diseases, X-Linked; Humans; Mutation; Peptides; Piperidines; Platelet Activation; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018

Article

Year

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Haematologica, 2018, Volume: 103, Issue:12

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Benzamides; Blood Platelets; Carrier Proteins; Genetic Diseases, X-Linked; Humans; Mutation; Peptides; Piperidines; Platelet Activation; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines

2018